We demonstrated that CK2 inhibitors cooperate with bortezomib in causing MM and MCL cell apoptosis by down modulating the signalling cascades of NF-κB and STAT3 and by potentiating the proteotoxic effects due to proteasome blockage. The gene discussed is STAT3; the disease is Miyoshi myopathy.